Cargando…

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan

INTRODUCTION: This study described, in routine clinical practice in Japan, the patient characteristics, treatment patterns, and outcomes of female patients with HR + /HER2- metastatic breast cancer (MBC) who started abemaciclib treatment. METHODS: Clinical charts were reviewed for patients starting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nozawa, K., Terada, M., Onishi, M., Ozaki, Y., Takano, T., Fakhouri, W., Novick, D., Haro, J. M., Faris, L. H., Kawaguchi, T., Tanizawa, Y., Tsurutani, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284953/ https://www.ncbi.nlm.nih.gov/pubmed/37217763 http://dx.doi.org/10.1007/s12282-023-01461-6

Ejemplares similares

A systematic literature review of prognostic factors in patients with HR+/HER2− advanced breast cancer in Japan
por: Hattori, Masaya, et al.
Publicado: (2021)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
por: Rugo, Hope S., et al.
Publicado: (2022)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer
por: Hao, Chunfang, et al.
Publicado: (2022)

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
por: Rugo, Hope S., et al.
Publicado: (2023)

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
por: Masuda, Jun, et al.
Publicado: (2023)

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
por: Wei, Qiran, et al.
Publicado: (2023)

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
por: Toi, Masakazu, et al.
Publicado: (2021)

Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan
por: Chen, Yucherng, et al.
Publicado: (2021)

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
por: Goetz, Matthew P., et al.
Publicado: (2020)

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2
por: Toi, Masakazu, et al.
Publicado: (2022)

Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib
por: Smyth, Emily Nash, et al.
Publicado: (2022)

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)
por: Blanch, Salvador, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective
por: Wang, Yingcheng, et al.
Publicado: (2021)

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
por: Zhang, Qing Yuan, et al.
Publicado: (2020)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy
por: Davie, Alison, et al.
Publicado: (2023)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

A Nomogram for Identifying HR+/Her2− Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy
por: Yang, Hanzhao, et al.
Publicado: (2023)

Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea
por: Novick, Diego, et al.
Publicado: (2022)

Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)
por: Masuda, Hiroko, et al.
Publicado: (2023)

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
por: Hamilton, Erika, et al.
Publicado: (2022)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
por: Paluch-Shimon, Shani, et al.
Publicado: (2023)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)
por: Yokoe, Takamichi, et al.
Publicado: (2021)

Abemaciclib for breast cancer
Publicado: (2020)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments
por: Nawa, Hideki, et al.
Publicado: (2021)

Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation
por: Takada, Shinya, et al.
Publicado: (2023)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)
por: Sakai, Hitomi, et al.
Publicado: (2023)

Abemaciclib does not increase the corrected QT interval in healthy participants
por: Chappell, Jill C., et al.
Publicado: (2023)

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center
por: Dannehl, Dominik, et al.
Publicado: (2022)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
por: Modi, Natansh D., et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report)
por: Panebianco, Martina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fcvfckusmja85076h2p8prepi0